Dr. Reddy’s Laboratories (RDY) has issued a statement refuting a recent report that claimed the company has reduced its workforce costs by 25% due to margin pressures linked to the drug Revlimid. The company categorically denied these assertions, stating that the information provided in the news article is incorrect.
In response to the report, Dr. Reddy's emphasized that it does not engage in commenting on market speculation and assured stakeholders that no significant events have occurred that would necessitate disclosure under the Securities and Exchange Board of India (SEBI) Listing Regulations. The company maintains that the claims made in the article do not reflect its current operational activities or financial strategies.
